基因组前列腺评分在极低至中危前列腺癌男性中的临床效用
本研究回顾性分析了城市三级学术医疗中心3年内134例男性的基因组前列腺评分结果,发现加入评分后23.9%的患者NCCN风险组发生改变;极低危组无改变,低危组42.2%改变,中危组22.4%改变;但临床管理决策并不总是反映这些改变。
要点
- 134例男性中,加入基因组前列腺评分后32例(23.9%)NCCN风险组改变。
- 极低危组31例风险组均未改变,低危组45例中19例(42.2%)改变,中危组58例中13例(22.4%)改变。
- 风险改变后主动监测选择率各异,但管理决策并非总与风险改变一致。
核心结论
- 基因组前列腺评分对极低危患者临床用处有限,因NCCN风险组未改变;对低危和中危男性可能更有用,32例(31%)风险组被重新分类,但临床管理决策并不总是反映这些改变。
研究设计与样本
- 回顾性研究,在城市三级学术医疗中心临床实践中进行,复习3年期间所有基因组前列腺评分结果,共134例男性。
主要发现
- 134例男性中,根据NCCN指南,31例(23.1%)为极低危,45例(33.6%)为低危,58例(43.3%)为中危。
- 加入评分后,134例中32例(23.9%)风险组改变;极低危组31例均未改变。
- 低危组45例中19例(42.2%)风险改变,其中15例降至极低危,4例升至中危。
- 中危组58例中13例(22.4%)风险改变,其中12例降至低危,1例升至高危。
- 低危转极低危的15例中9例(60%)选择主动监测。
关键数值与推荐
- 中危转低危的12例中,9例(75%)选择主动监测,2例(16.7%)选择根治性治疗,1例(8.3%)选择未知。
- 中危未改变风险的45例中,28例(62.2%)选择根治性治疗,12例(26.0%)选择主动监测,5例(11.1%)选择未知。
- 低危升中危的4例中,2例选择根治性治疗,2例选择主动监测。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We retrospectively investigated the Genomic Prostate Score® assay in clinical practice at an urban tertiary care academic center. MATERIALS AND METHODS: We reviewed all Genomic Prostate Score results acquired during a 3-year period. Changes in patient NCCN® (National Comprehensive Cancer Network®) risk group, including very low, low, intermediate or high risk, and ultimate management decisions were recorded. RESULTS: Genomic Prostate Score risk stratification was performed in 134 men. According to the NCCN Guidelines®, 31 of the 134 men (23.1%) were at very low risk, 45 (33.6%) were at low risk and 58 (43.3%) were at intermediate risk. After adding the score the risk group changed in 32 of 134 patients (23.9%). The risk group did not change in the 31 men at very low risk. However, in the low risk group the risk changed in 19 of the 45 men (42.2%), including in 15 to very low and in 4 to intermediate risk. Also, in the intermediate risk group the risk changed in 13 of the 58 men (22.4%), including to low in 12 and to high risk in 1. Nine of the 15 men (60%) in whom risk changed from low to very low elected active surveillance. Nine of the 12 patients (75%) at intermediate risk in whom risk changed to low risk elected active surveillance, 2 (16.7%) elected definitive therapy and in 1 (8.3%) the choice was unknown. Of the 45 men at intermediate risk in whom risk was unchanged 28 (62.2%) elected definitive therapy, 12 (26.0%) elected active surveillance and in 5 (11.1%) the choice was unknown. Of the 4 men upgraded from low to intermediate risk after adding the genomic prostate score 2 elected definitive therapy and 2 chose active surveillance. CONCLUSIONS: The Genomic Prostate Score has limited clinical usefulness in patients at very low risk since the NCCN risk group did not change. While it may be more useful for men at low and intermediate risk, for 32 (31%) of whose risk group was reclassified, clinical management decisions did not always appear to reflect these changes.
引用
- Gaffney C, Golan R, Cantu MD, et al. The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer. J Urol. 2019. PMID: 30933552. doi:10.1097/JU.0000000000000170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。